FDA Peptide Reclassification 2026: What It Means for Providers The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like Dihexa Peptide: Complete Guide to Synaptogenesis (2026) The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like FDA Removes 12 Peptides from 503A Category 2 Newtropin FDA approvals February 2026